Sputum Myeloperoxidase in Chronic Obstructive Pulmonary Disease

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2014 Mar 5

PMID 24588870

Citations 24

Authors

Alling Zhu

Dehai Ge

Jingying Zhang

Yue Teng

Cheng Yuan

Mao Huang

Ian M Adcock

Peter J Barnes

Xin Yao

Affiliations

Soon will be listed here.

Abstract

Background: Airway inflammation, especially neutrophilic airway inflammation, is a cardinal pathophysiologic feature in chronic obstructive pulmonary disease (COPD) patients. The ideal biomarkers characterizing the inflammation might have important potential clinical applications in disease assessment and therapeutic intervention. Sputum myeloperoxidase (MPO) is recognized as a marker of neutrophil activity. The purpose of this meta-analysis is to determine whether sputum MPO levels could reflect disease status or be regulated by regular medications for COPD.

Methods: Studies were identified by searching PubMed, Embase, the Cochrane Database, CINAHL and http://www.controlled-trials.com for relevant reports published before September 2012. Observational studies comparing sputum MPO in COPD patients and healthy subjects or asthmatics, or within the COPD group, and studies comparing sputum MPO before and after treatment were all included. Data were independently extracted by two investigators and analyzed using STATA 10.0 software.

Results: A total of 24 studies were included in the meta-analysis. Sputum MPO levels were increased in stable COPD patients when compared with normal controls, and this increase was especially pronounced during exacerbations as compared with MPO levels during the stable state. Theophylline treatment was able to reduce MPO levels in COPD patients, while glucocorticoid treatment failed to achieve the same result.

Conclusion: Sputum MPO might be a promising biomarker for guiding COPD management; however, further investigations are needed to confirm this.

Citing Articles

Hyperbaric oxygen potentiates platelet-rich plasma composition and accelerates bone healing.

Chang W, Huang C, Chen T, Chao S, Lin C, Chang C J Orthop Translat. 2025; 51:1-12.

PMID: 39902098 PMC: 11787568. DOI: 10.1016/j.jot.2024.10.016.

D-Dimers and MPO Are No Suitable Biomarkers for Application in Abdominal Aortic Aneurysm (AAA) Surveillance in a Real-World Setting of Vascular Surgery Patients.

Siegrist H, Spieler A, Peters A, Passek K, Bockler D, Dihlmann S Biomolecules. 2025; 14(12.

PMID: 39766232 PMC: 11673383. DOI: 10.3390/biom14121525.

The Roles of Neutrophil-Derived Myeloperoxidase (MPO) in Diseases: The New Progress.

Lin W, Chen H, Chen X, Guo C Antioxidants (Basel). 2024; 13(1).

PMID: 38275657 PMC: 10812636. DOI: 10.3390/antiox13010132.

Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.

Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Biomedicines. 2023; 11(12).

PMID: 38137330 PMC: 10740779. DOI: 10.3390/biomedicines11123109.

Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review.

Rezaeeyan H, Arabfard M, Rasouli H, Shahriary A, Gh B Immun Inflamm Dis. 2023; 11(11):e1090.

PMID: 38018577 PMC: 10659759. DOI: 10.1002/iid3.1090.

References

Hurst J, Perera W, Wilkinson T, Donaldson G, Wedzicha J . Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 173(1):71-8. DOI: 10.1164/rccm.200505-704OC. View

ODonnell C, Newbold P, White P, Thong B, Stone H, Stockley R . 3-Chlorotyrosine in sputum of COPD patients: relationship with airway inflammation. COPD. 2010; 7(6):411-7. DOI: 10.3109/15412555.2010.528086. View

Gompertz S, Hill A, Bayley D, Stockley R . Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency. Respir Med. 2005; 100(6):1094-9. DOI: 10.1016/j.rmed.2005.09.024. View

Keatings V, Jatakanon A, Worsdell Y, Barnes P . Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997; 155(2):542-8. DOI: 10.1164/ajrccm.155.2.9032192. View

Fens N, de Nijs S, Peters S, Dekker T, Knobel H, Vink T . Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J. 2011; 38(6):1301-9. DOI: 10.1183/09031936.00032911. View

Pettersen C, Adler K . Airways inflammation and COPD: epithelial-neutrophil interactions. Chest. 2002; 121(5 Suppl):142S-150S. DOI: 10.1378/chest.121.5_suppl.142s. View

Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C . Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease. Respir Med. 2009; 103(7):1056-62. DOI: 10.1016/j.rmed.2009.01.011. View

Cantin A, North S, Fells G, Hubbard R, Crystal R . Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987; 79(6):1665-73. PMC: 424497. DOI: 10.1172/JCI113005. View

Churg A, Marshall C, Sin D, Bolton S, Zhou S, Thain K . Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 185(1):34-43. DOI: 10.1164/rccm.201103-0468OC. View

10.

Xu S, Carlson M, Engstrom A, Garcia R, PETERSON C, Venge P . Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest. 1994; 54(5):365-76. DOI: 10.3109/00365519409088436. View

11.

Rytila P, Rehn T, Ilumets H, Rouhos A, Sovijarvi A, Myllarniemi M . Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res. 2006; 7:69. PMC: 1524947. DOI: 10.1186/1465-9921-7-69. View

12.

Bathoorn E, Liesker J, Postma D, Koeter G, van der Toorn M, Van der Heide S . Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009; 4:101-9. PMC: 2672798. DOI: 10.2147/copd.s4854. View

13.

Parr D, White A, Bayley D, Guest P, Stockley R . Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res. 2006; 7:136. PMC: 1664562. DOI: 10.1186/1465-9921-7-136. View

14.

Metso T, Rytila P, Peterson C, Haahtela T . Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods. Respir Med. 2001; 95(1):48-55. DOI: 10.1053/rmed.2000.0970. View

15.

Stockley R, Bayley D, Hill S, Hill A, Crooks S, Campbell E . Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax. 2001; 56(5):366-72. PMC: 1746057. DOI: 10.1136/thorax.56.5.366. View

16.

Sapey E, Bayley D, Ahmad A, Newbold P, SNELL N, Stockley R . Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability. Thorax. 2007; 63(6):493-9. DOI: 10.1136/thx.2007.086751. View

17.

Gross N . Airway inflammation in COPD. Reality or myth?. Chest. 1995; 107(5 Suppl):210S-213S. DOI: 10.1378/chest.107.5_supplement.210s. View

18.

Ford P, Durham A, Russell R, Gordon F, Adcock I, Barnes P . Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010; 137(6):1338-44. DOI: 10.1378/chest.09-2363. View

19.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

20.

Stoller J, Snider G, Brantly M, Stockley R, Turino G, Konietzko N . [American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency]. Pneumologie. 2005; 59(1):36-68. DOI: 10.1055/s-2004-830176. View